NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Trevi Therapeutics, Inc. (TRVI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TRVI

$12.77

−$0.06 (−0.47%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRVI with… →

TRVI Key Statistics

As of Oct 21, 2026
Trading
Open
$12.83
Previous Close
$12.83
Day's Range
12.72–13.30
52-Week Range
9.82–20.22
Volume
2.62M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.98
Valuation
Market Cap
$1.82B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.35
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$42.76M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
142.48M
1-Year Return
+19.91%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
1.96M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TRVI closed at $12.77, +19.91% over 1 year.

Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $1.82B.

In fiscal 2025, TRVI reported revenue of $0.00.

TRVI Stock Return by Calendar Year

Trevi Therapeutics, Inc. (TRVI) return since May 2019: what $10,000 became

1 year
$10,000 $11,991
+19.91%
5 years
$10,000 $102,160
+921.60%
Since May 2019
$10,000 $16,185
+61.85%

If you had invested $10,000 in Trevi Therapeutics, Inc. (TRVI) at the close on May 7, 2019, the earliest close on record here, it would have been worth $16,185 at the close on October 21, 2026: +61.85% in total, +6.67% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.00%
2025+203.88%
2024+207.46%
2023−30.57%
2022+146.80%
2021−67.69%
2020−35.47%
2019 (partial year)−52.47%

As of October 21, 2026.

TRVI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$42.76M—
2024$0.00−$47.91M—
2023$0.00−$29.07M—
2022$0.00−$29.15M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$49.33M−$42.76M—
2024$0.00—−$51.52M−$47.91M—
2023$0.00—−$33.92M−$29.07M—
2022$0.00—−$29.91M−$29.15M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Trevi Therapeutics, Inc. (TRVI) is capitalised at $1.82B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 34.

Over the past 52 weeks the price has ranged from $9.82 to $20.22. The most recent close on file for TRVI is $12.77, dated October 21, 2026. That is −$0.06 (−0.47%) against the previous close. The latest close sits 30.04% above that 52-week low.

Financial Health

In fiscal 2025, Trevi Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $42.76M. Earnings per share on a trailing basis come to −0.35.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +19.91%. Measured over 5 years, that is +59.17% a year compounded. The reported beta is 0.98. Daily returns over the trailing 7 years annualize to a volatility of 97.2%.

Growth & Income

The record shows no dividend for TRVI.

2026 is still running; the total return is +2.00% year to date. Across the complete calendar years on file, 2024 returned +207.46% and 2021 returned −67.69%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

Trevi Therapeutics, Inc. (TRVI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Trevi Therapeutics, Inc. TRVI $1.82B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Trevi Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Visit website →